PACE A and PACE B trial - What a radiation oncologist needs to know.
作者信息
Kamat Shounak J, Basu Trinanjan, Sahu Jay P, Menon Rohith R, Gadekar Ajinkya, Roshan Ghazala K, Kurkure Durva A, Kabre Rohit, Talukdar Riddhijyoti
机构信息
Department of Radiation Oncology, HCG Cancer Centre, Mumbai-400092, India.
出版信息
J Radiosurg SBRT. 2025;9(3):257-260.
Abstract
摘要
相似文献
1
PACE A and PACE B trial - What a radiation oncologist needs to know.PACE A和PACE B试验——放射肿瘤学家需要了解的内容。
J Radiosurg SBRT. 2025;9(3):257-260.
2
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial.强度调制中度低分割放疗与立体定向体部放疗治疗前列腺癌（PACE-C）：一项随机、开放标签、3期、非劣效性试验的早期毒性结果
Lancet Oncol. 2025 Jul;26(7):936-947. doi: 10.1016/S1470-2045(25)00205-0. Epub 2025 Jun 12.
3
Primary Analysis of (NCT03380806) a Phase II Randomized Trial of Stereotactic Body Radiotherapy Boost Versus Conventional Fractionation External Beam Radiotherapy Boost in Unfavorable-Intermediate and High-Risk Prostate Cancer.（NCT03380806）一项关于立体定向体部放射治疗增敏与传统分割外照射放疗增敏在中高危前列腺癌患者中的II期随机试验的初步分析
Prostate. 2025 Jul;85(10):977-985. doi: 10.1002/pros.24905. Epub 2025 Apr 27.
4
Salvage stereotactic body radiation therapy for locally recurrent prostate cancer following primary radiation therapy, are benefits worth toxicity risks?: A systematic review.挽救性立体定向体部放射治疗在原发性放射治疗后局部复发性前列腺癌中的作用：毒性风险值得获益吗？：系统评价。
Prostate. 2023 May;83(6):489-497. doi: 10.1002/pros.24491. Epub 2023 Jan 30.
5
Online Adaptive Five-Fraction Ablative Radiotherapy for Prostate Cancer Using a Conventional Linear Accelerator.使用传统直线加速器的前列腺癌在线自适应五分割消融放疗
Pract Radiat Oncol. 2025 Jul-Aug;15(4):e371-e381. doi: 10.1016/j.prro.2025.01.013. Epub 2025 Feb 12.
6
Chronic Prostate Cancer-Related Symptoms and Toxicities Following Stereotactic Body Radiation Therapy: Implications for Future Radionuclide Therapy.立体定向体部放射治疗后慢性前列腺癌相关症状及毒性反应：对未来放射性核素治疗的启示
Cureus. 2025 May 29;17(5):e85034. doi: 10.7759/cureus.85034. eCollection 2025 May.
7
Stereotactic body radiation therapy (SBRT) for high-risk prostate cancer: Where are we now?立体定向体部放射治疗（SBRT）治疗高危前列腺癌：现状如何？
Pract Radiat Oncol. 2018 May-Jun;8(3):185-202. doi: 10.1016/j.prro.2017.11.008. Epub 2017 Dec 2.
8
Stereotactic Body Radiation Therapy for Stage IIA to IIIA Inoperable Non-Small Cell Lung Cancer: A Phase 1 Dose-Escalation Trial.体部立体定向放疗治疗不可手术的 IIA 期至 IIIA 期非小细胞肺癌：1 期剂量递增试验。
Int J Radiat Oncol Biol Phys. 2024 Jul 1;119(3):869-877. doi: 10.1016/j.ijrobp.2023.12.018. Epub 2023 Dec 26.
9
Adapting Safety Plans for Autistic Adults with Involvement from the Autism Community.在自闭症群体的参与下为成年自闭症患者调整安全计划。
Autism Adulthood. 2025 May 28;7(3):293-302. doi: 10.1089/aut.2023.0124. eCollection 2025 Jun.
10
Theorising survivorship after intensive care: A systematic review of patient and family experiences.重症监护后生存状况理论化：对患者和家属体验的系统回顾。
J Clin Nurs. 2021 Sep;30(17-18):2584-2610. doi: 10.1111/jocn.15766. Epub 2021 Apr 7.
本文引用的文献
1
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.立体定向体部放射治疗局限性前列腺癌的 3 期临床试验。
N Engl J Med. 2024 Oct 17;391(15):1413-1425. doi: 10.1056/NEJMoa2403365.
2
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.前列腺癌监测、手术或放疗后 15 年的结果。
N Engl J Med. 2023 Apr 27;388(17):1547-1558. doi: 10.1056/NEJMoa2214122. Epub 2023 Mar 11.
3
Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial.高危和极高危前列腺癌的前列腺放疗与全盆腔放疗比较（POP-RT）：来自 III 期随机对照试验的结果。
J Clin Oncol. 2021 Apr 10;39(11):1234-1242. doi: 10.1200/JCO.20.03282. Epub 2021 Jan 26.
4
Study protocol of a randomised controlled trial of prostate radiotherapy in high-risk and node-positive disease comparing moderate and extreme hypofractionation (PRIME TRIAL).一项比较中危和高危伴淋巴结转移前列腺癌患者采用中度和大分割放疗的随机对照临床试验方案（PRIME TRIAL）。
BMJ Open. 2020 Feb 28;10(2):e034623. doi: 10.1136/bmjopen-2019-034623.
5
Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer.随机分组试验：一种低分割辐射方案治疗局限性前列腺癌。
J Clin Oncol. 2017 Jun 10;35(17):1884-1890. doi: 10.1200/JCO.2016.71.7397. Epub 2017 Mar 15.
6
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.常规分割与大分割高剂量调强放疗治疗前列腺癌：随机、非劣效性3期CHHiP试验的5年结果
Lancet Oncol. 2016 Aug;17(8):1047-1060. doi: 10.1016/S1470-2045(16)30102-4. Epub 2016 Jun 20.
7
Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer.比较低危前列腺癌患者两种放疗分割方案的随机 III 期非劣效性研究。
J Clin Oncol. 2016 Jul 10;34(20):2325-32. doi: 10.1200/JCO.2016.67.0448. Epub 2016 Apr 4.
8
Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.对于前列腺癌患者，采用低分割与常规分割放射治疗（HYPRO）：一项随机、非劣效性、3 期试验的晚期毒性结果。
Lancet Oncol. 2016 Apr;17(4):464-474. doi: 10.1016/S1470-2045(15)00567-7. Epub 2016 Mar 9.
9
Prostate alpha/beta revisited -- an analysis of clinical results from 14 168 patients.重新审视前列腺的 α/β 受体——14168 例患者的临床结果分析。
Acta Oncol. 2012 Nov;51(8):963-74. doi: 10.3109/0284186X.2012.719635. Epub 2012 Sep 12.
10
Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991.EORTC 试验 22991 中中高危局限性前列腺癌根治性放疗的急性毒性。
Eur J Cancer. 2009 Nov;45(16):2825-34. doi: 10.1016/j.ejca.2009.07.009. Epub 2009 Aug 12.
Zotero 插件